Litcius/Paper detail

Parkinson’s disease laterality: a 11C-PE2I PET imaging study

Andreas–Antonios Roussakis, Zhou Zeng, Nicholas P Lao–Kaim, Antonio Martín‐Bastida, Paola Piccini, Roger A. Barker, Krista Farrell, Natalie Valle Guzman, Xiufang He, Stanley E. Lazic, Sarah A. Moore, Robert C. Morris, Pamela Tyers, Ruwani Wijeyekoon, Danielle Daft, Sam Hewitt, Biswas Dayal, Thomas Foltynie, Zenobia Kefalopoulou, Philipp Mahlknecht, Hjálmar Bjartmarz, Anders Björklund, Olle Lindvall, Jenny Nelander-Wahlestedt, Malin Parmar, Gesine Paul, Håkan Widner, Alistair Church, Stephen B. Dunnett, Kathryn J. Peall, Anne Rosser, Jean Marc Gurruchaga, Stéphane Palfi, Tobias Piroth, Christian Winkler

2020Journal of Neurology11 citationsDOIOpen Access PDF

Abstract

Abstract Asymmetry of striatal dopaminergic deficits and motor symptoms is a typical characteristic of idiopathic Parkinson’s disease (PD). This study aims to characterise the trend of asymmetry in moderate-stage PD. We performed a 19-month longitudinal study in 27 patients with PET-CT imaging and appropriate clinical assessments. 11 C-PE2I non-displaceable binding potential (BP ND ) was calculated bilaterally for the striatum at baseline and follow-up to estimate the in vivo density of striatal dopamine transporters (DAT). Changes in striatal 11 C-PE2I BP ND over time were more prominent in the ipsilateral as compared to contralateral side. Changes in MDS-UPDRS-III (motor component of the Movement Disorders Society Unified PD Rating Scale) were not different between the clinically most and least affected body sides. Our data support that the asymmetry in striatal dopaminergic degeneration becomes less prominent in moderate-stage PD. In contrast, during the above period, the asymmetry of motor symptoms was maintained between the clinically most and least affected body sides.

Topics & Concepts

DopaminergicDopamine transporterParkinson's diseaseStriatumNeurologyMedicineLateralityPsychologyBinding potentialNeuroradiologyDopamineNeuroscienceInternal medicineDiseaseParkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatmentsBotulinum Toxin and Related Neurological Disorders
Parkinson’s disease laterality: a 11C-PE2I PET imaging study | Litcius